Evommune, Inc. (EVMN) is a Healthcare stock trading at $13.95 (as of 2026-08-21), with a market capitalization of $506.27M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Evommune, Inc. is a clinical-stage biotechnology company developing therapies aimed at drivers of chronic inflammatory diseases. Its initial clinical programs focus on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis, including EVO756 (CSU/AD) and EVO301 (AD/UC).
Understand Evommune, Inc.: how it makes money
Evommune develops clinical-stage therapies for chronic inflammatory diseases, with product candidates EVO756 and EVO301 targeting CSU, atopic dermatitis, and ulcerative colitis. At present, it reports no revenue, so value depends on advancing these programs through clinical development.
The profit engine for Evommune is whether its clinical development programs for EVO756 and EVO301 can demonstrate success in defined trial endpoints, so the company can continue progressing its therapies for CSU, atopic dermatitis, and ulcerative colitis.
Business quality (Weak): Clinical-stage biotech with no reported revenue and a large operating loss, so the key observable progress is trial performance for its named product candidates, not current commercial results.
Bull case
Target-specific development programs: Evommune is focused on therapies targeting key drivers of chronic inflammatory diseases, with initial programs in chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Product candidates with reported clinical performance indicators: Trial-related metrics shown include a 99.8% Posterior Distribution Meeting Bayesian Success Criterion and a 33.0% Placebo-Adjusted Eczema Area and Severity Index Improvement at Week 12.
Multiple shots on goal across indications: The company is developing EVO756 and EVO301 across more than one disease area, which can broaden the opportunity if outcomes are favorable.
Bear case
No reported revenue and significant operating loss: For the latest period shown (2025-09-30), revenue is reported as 0.0B and operating margin is -133.3%, reflecting ongoing investment with no current commercial contribution.
Clinical success is uncertain: Because the company is clinical-stage, future outcomes depend on whether trial endpoints continue to be met, and there is risk that further study could fail to replicate or extend these results.
Progress can be sensitive to enrollment and study outcomes: The provided metrics reference dose-ranging enrollment and patient counts in active and placebo arms, and results can be influenced by study conduct and the distribution of patient outcomes.